Article Text


Viral hepatitis
P69 Hepatitis delta RNA level and genotype, and hepatitis B surface antigen titre predict response to PEG-interferon in the treatment of chronic hepatitis delta virus
  1. S Hughes,
  2. I Carey,
  3. D Shang,
  4. M Horner,
  5. M Bruce,
  6. I Fletcher,
  7. T J S Cross,
  8. A Suddle,
  9. K Agarwal,
  10. P M Harrison
  1. Institute of Liver Studies, King's College Hospital, UK


Introduction Hepatitis Delta Virus (HDV) infection is associated with more severe liver disease in individuals with hepatitis B virus (HBV). The only treatment for HDV shown to be of benefit is α-interferon, but predictors of response to therapy are not known.

Aim To evaluate the efficacy of PEG-interferon α 2a (PEG-IFN) therapy and factors predicting viral response in patients with chronic HBV/HDV co-infection.

Method Between 2005 and 2010, 14 patients (71% female, median age 32, 57% Black African, 36% Caucasian, 7% Oriental, 79% HBeAg −ve, 100% HDV RNA +ve, 64% HDV genotype 1, 29% HDV genotype 5, 7% HDV genotype 6, 43% cirrhotic) were treated with PEG-IFN 180 mcg/week for a median of 48 weeks. The median follow-up post treatment was 16.5 months. A retrospective analysis was undertaken to assess clinical and virological factors predictive of outcome. HDV RNA was measured by an in-house real-time quantitative PCR assay (range 6.4×102 to 6.4×107 copies/ml), and genotyping was performed by comparison of nucleotide sequences of HDV RNA with previously reported sequences of HDV genotypes 1–8. HBV DNA was measured using the Roche COBAS Ampliprep/TaqMan assay. Hepatitis B surface antigen (HBsAg) titres were measured using the Abbott Architect assay.

Results In response to PEG-IFN, 64% cleared HDV RNA by end of treatment (EOT), 1 patient with genotype 1 HDV relapsed and 54% remain HDV RNA −ve beyond 24 weeks post-treatment (sustained virological response; SVR); 2 patients subsequently cleared HBsAg. Baseline HDV RNA was significantly higher in non-responders compared to those with SVR (2.1×106 vs 1.3×104 copies/ml, p=0.003) and predicted treatment response (AUROC=1.0, p=0.003). A HDV RNA of >1.96×105 copies/ml predicted treatment failure (p=0.001, positive predictive value 100% and sensitivity 100%). There was a strong correlation between HDV RNA level and HBsAg titre (r=0.82, p<0.001). Baseline HBsAg titre was significantly higher in non-responders compared to those with SVR (10 067 vs 5820 IU/ml, p=0.007) and also predicted treatment response (AUROC 0.95, p=0.007). A cut-off HBsAg titre of >9000 IU/ml predicted treatment failure (p=0.021, positive predictive value 100% and sensitivity of 67%). All patients with HDV genotype non-1 achieved SVR, compared with only 25% of those with HDV genotype 1 (p=0.02). Responders were similar to non-responders with respect to gender, age, liver histology staging and pre-treatment ALT.

Conclusion PEG-IFN was an effective treatment for chronic HDV, with 54% achieving SVR. Levels of HDV RNA >1.96x105 copies/mL and HBsAg titres >9000 IU/ml predicted treatment failure, whereas HDV genotype non-1 predicted long-term viral clearance.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.